MEDI-528: Completed Phase IIb enrollment

Ligand disclosed in its 4Q10 earnings that AstraZeneca's MedImmune LLC unit completed enrollment of

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE